囊性纤维化药物开发管道的进展
Christine Esposito1, Martin Kamper1, Jessica Trentacoste1
1Division of Pulmonary, Critical Care and Sleep Medicine, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York, NY 11042, USA.
Life (Basel, Switzerland)
|September 28, 2023
概括
囊性纤维化治疗正在进步,改善了患者的生活质量和生存率. 包括遗传方法在内的新疗法旨在为这种进展性遗传疾病提供治疗方法.
科学领域:
- 医学研究 医学研究
- 遗传学 是一个遗传学.
- 肺部病理学 肺部病理学
背景情况:
- 囊性纤维化 (CF) 是一种进展性遗传疾病,影响多个器官,主要是呼吸道和胃肠道系统.
- 在CF患者中显著的发病率和死亡率需要先进的治疗来减缓疾病的进展和延长预期寿命.
- 虽然目前的疗法已经改善了生活质量和生存率,但对CF的确切治疗仍然难以捉摸.
研究的目的:
- 审查目前用于囊性纤维化的主要治疗方法.
- 讨论CF药物开发管道中的新兴治疗方法.
- 探索CF的新型遗传疗法,特别是对于那些对当前调节器无反应的患者.
主要方法:
- 审查目前的囊性纤维化跨膜导电性调节器 (CFTR) 调节器疗法.
- 对抗炎症和抗感染治疗策略的分析.
- 对CF的基因疗法,RNA疗法和基因编辑方法的探索.
主要成果:
- 目前的治疗方法提高了患者的生活质量,减少了症状负担,并增加了生存率.
- 高效调节器疗法 (HEMT) 针对CFTR蛋白恢复.
- 像RNA疗法,基因转移和基因编辑等新兴疗法显示出潜在治愈的希望.
结论:
- 在治疗囊性纤维化方面取得了重大进展,但仍然需要治愈.
- 新的治疗策略,特别是基因疗法,正在研究中,以解决CF治疗的未满足需求.
- 未来的研究重点是为所有CF患者开发治愈疗法,包括那些没有受益于当前调节器疗法的患者.
相关概念视频
Cystic Fibrosis: Management
185
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
185
Cystic Fibrosis: Pathogenesis
269
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
269
Drugs for Treatment of Constipation-Predominant IBS
197
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
197
Carrier-Mediated Transport
460
Carrier-mediated transport is a pivotal process in drug absorption, particularly for lipid-insoluble drugs, and encompasses facilitated diffusion and active transport. Facilitated diffusion allows drugs to move along their concentration gradient without energy expenditure, while active transport utilizes ATP to drive drug movement against this gradient.
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
Active transport involves two types of membrane-spanning transporters: uptake and efflux. Uptake transporters are expressed in the small...
460
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Antiasthma Drugs: Leukotriene Modifiers
338
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
338


